Transcriptome Alterations in Liver Metastases of Colorectal Cancer After Acquired Resistance to Cetuximab.

ABSTRACT:

Background/aim

Cetuximab in combination with chemotherapy is recommended as first-line therapy for metastatic colorectal cancer (mCRC) with wild-type RAS. However, drug resistance to cetuximab exists widely in mCRC and reduces the prognosis of patients. Although some genomic alterations have been demonstrated to drive acquired resistance to cetuximab, the overall compendium of inherent molecular mechanisms is still incomplete.

Materials and methods

Four liver metastasis biopsies were collected from two mCRC patients who were treated with cetuximab in combination with 5-fluororacil plus leucovorin and oxaliplatin (FOLFOX) regimen.

Results

Transcriptomic analysis revealed global gene expression alterations between paired samples prior to treatment and after acquired res

SUBMITTER: Li Z 

PROVIDER: S-EPMC6542644 | biostudies-literature | 2019 May-Jun

REPOSITORIES: biostudies-literature